Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials
James B. Hermiller1*, MD, FSCAI, FACC; Krishnankutty Sudhir2, MD, PhD; Robert J. Applegate3, MD; Ali Rizvi1, MD; John Wang4, MD; Paul C. Gordon5, MD; Manejeh Yaqub2, MD; Sherry Cao2, MS; Joanne M. Ferguson2, RN; Robert S. Smith, Jr.2, PhD; Poornima Sood2, MD, MBA, MPhil; Gregg W. Stone6, MD
1. The Heart Center of Indiana, Indianapolis, IN, USA; 2. Abbott Vascular, Santa Clara, CA, USA; 3. Wake Forest University Health Sciences, Winston-Salem, NC, USA; 4. Union Memorial Hospital, Baltimore, MD, USA; 5. The Miriam Hospital,
Aims: The impact of age on outcomes following everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) implantation was evaluated in a p
